DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Chimeric Antigen Receptor (CAR) T-Cell Therapy | Access & Reimbursement | US | 2023
CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Janssen’s Carvykti, have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and patients…
Attention-Deficit-Hyperactivity Disorder – Access & Reimbursement – Access and Reimbursement – Attention-Deficit/Hyperactivity Disorder (US)
Attention-deficit / hyperactivity disorder (ADHD) is a common childhood disorder that can persist through adolescence and into adulthood, although diagnosis and treatment initiation can occur at…
Immune Thrombocytopenic Purpura | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2023
Immune thrombocytopenic purpura (ITP) is an autoimmune disease resulting in a low platelet count. Treatment of ITP involves the use of immunomodulators and corticosteroids as well as multiple…
Dry and Wet Age-Related Macular Degeneration – Geographic Focus: China – Dry and Wet Age-Related Macular Degeneration – China In-Depth (China)
Age-related macular degeneration (AMD), which includes dry and wet AMD, is a leading cause of irreparable vision loss globally. In China, patients with wet AMD are typically treated with VEGF…
Type 2 Diabetes – Access & Reimbursement – Access & Reimbursement – Type 2 Diabetes (US)
The sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are frequently prescribed for type 2 diabetes (T2D). These classes, along with glucose-…
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis/Atopic Eczema – China In-Depth (China )
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczema that significantly affects patients’ quality of life. It is traditionally treated with…
